ArticleJournal for immunotherapy of cancer2022

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.

Timothy A Yap et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.